Trial · NCT02839707
Adverse events1,416
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,416
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Arm I (PLD, Atezolizumab) | 55 | 111 | |
| other | Anemia | Blood and lymphatic system disorders | Arm II (PLD, Bevacizumab, Atezolizumab) | 62 | 160 | |
| other | Anemia | Blood and lymphatic system disorders | Arm III (PLD, Bevacizumab) | 63 | 154 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Arm I (PLD, Atezolizumab) | 1 | 111 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Arm II (PLD, Bevacizumab, Atezolizumab) | 2 | 160 | |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Arm III (PLD, Bevacizumab) | 1 | 154 | |
| other | Hemolysis | Blood and lymphatic system disorders | Arm I (PLD, Atezolizumab) | 0 | 111 | |
| other | Hemolysis | Blood and lymphatic system disorders | Arm II (PLD, Bevacizumab, Atezolizumab) | 0 | 160 | |
| other | Hemolysis | Blood and lymphatic system disorders | Arm III (PLD, Bevacizumab) | 1 | 154 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Arm I (PLD, Atezolizumab) | 0 | 111 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Arm II (PLD, Bevacizumab, Atezolizumab) | 3 | 160 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Arm III (PLD, Bevacizumab) | 1 | 154 | |
| other | Lymph node pain | Blood and lymphatic system disorders | Arm I (PLD, Atezolizumab) | 0 | 111 | |
| other | Lymph node pain | Blood and lymphatic system disorders | Arm II (PLD, Bevacizumab, Atezolizumab) | 2 | 160 | |
| other | Lymph node pain | Blood and lymphatic system disorders | Arm III (PLD, Bevacizumab) | 0 | 154 | |
| other | Atrial fibrillation | Cardiac disorders | Arm I (PLD, Atezolizumab) | 1 | 111 | |
| other | Atrial fibrillation | Cardiac disorders | Arm II (PLD, Bevacizumab, Atezolizumab) | 3 | 160 | |
| other | Atrial fibrillation | Cardiac disorders | Arm III (PLD, Bevacizumab) | 1 | 154 | |
| other | Chest pain - cardiac | Cardiac disorders | Arm I (PLD, Atezolizumab) | 1 | 111 | |
| other | Chest pain - cardiac | Cardiac disorders | Arm II (PLD, Bevacizumab, Atezolizumab) | 0 | 160 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02839707/events